This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Neurology  • Cerebrovascular Disease  • Cardiovascular System  • Alert me on articles by topic  Social Bookmarking   What's this?

Neurologists, Get Off Your Hands!

Steven H. Horowitz, MD

Arch Neurol. 1998;55:155-157.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I was privileged to have been one of the original principal investigators in the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group¹(NINDS rt-PA) and a coauthor of the seminal publication of the results. This study directly led to the Food and Drug Administration's approval of the thrombolytic agent, tissue-type plasminogen activator (t-PA), on June 18, 1996, as the first and, thus far, only accepted therapy specifically directed at acute ischemic stroke. As such, during the last year, I have been an invited lecturer on this treatment at a variety of medical centers, large and small. I am writing to convey my impressions of the lack of enthusiasm for this therapy exhibited by neurologists at places where I have spoken. Rather than embrace, or at least acknowledge, this as the first step in the treatment of neurology's most common serious and debilitating disease . . . [Full Text of this Article]

From the Division of Neurology, Department of Psychiatry and Neurology, University of Missouri, Columbia School of Medicine, Columbia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Commentary on NICE guidelines for alteplase for the treatment of acute ischaemic stroke
Lindley
Heart 2007;93:1617-1618.
FULL TEXT  

Distinguishing Between Stroke and Mimic at the Bedside: The Brain Attack Study
Hand et al.
Stroke 2006;37:769-775.
ABSTRACT | FULL TEXT  

Cuyahoga County Operation Stroke Speed of Emergency Department Evaluation and Compliance With National Institutes of Neurological Disorders and Stroke Time Targets
Katzan et al.
Stroke 2003;34:994-998.
ABSTRACT | FULL TEXT  

The Imperative to Develop Dedicated Stroke Centers
Barnett and Buchan
JAMA 2000;283:3125-3126.
FULL TEXT  

Trials of Thrombolysis in Acute Ischemic Stroke : Does the Choice of Primary Outcome Measure Really Matter?
Wardlaw et al.
Stroke 2000;31:1133-1135.
ABSTRACT | FULL TEXT  

Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
Buchan et al.
Neurology 2000;54:679-679.
ABSTRACT | FULL TEXT  

Stroke thrombolysis: Is tissue plasminogen activator a defibrillator for the brain?
Buchan and Feasby
CMAJ 2000;162:47-48.
FULL TEXT  

Tissue-Type Plasminogen Activator
Pittman and Horowitz
Arch Neurol 1998;55:1377-1378.
FULL TEXT  

Thrombolytic Therapy in Acute Stroke
Landau
Arch Neurol 1998;55:1378-1378.
FULL TEXT